Full text is available at the source.
Abstract
The vaccine encoding tumor-specific antigens with optimized flanking sequences cleared established tumors and elicited robust CD8+ T-cell responses.
- Two mRNA vaccines were designed to encode the same tumor-specific antigens but differed in their epitope-flanking amino acids.
- The vaccine with optimized flanking sequences (TSA-Opti) was associated with stronger immune responses compared to the one with natural flanking sequences (TSA-Nat).
- Quantitative analysis indicated that TSA-Opti increased the levels of antigen presentation.
- Enhanced antigen presentation correlated with greater magnitude, clonal diversity, and functionality of CD8+ T cells specific to the tumor antigens.
- TSA-Opti also promoted durable immune memory, suggesting long-term protection against tumor re-exposure.
Simplified
mRNA Technology